NEW YORK (dpa-AFX) – After the brilliant start to the week, the US leading index Dow added a little extra on Tuesday. He advanced 0.47 percent to 29,295 points. The day before, the leading index had reached a record high in early trading and was close to the 30,000 mark. He was driven by the prospect of an effective vaccine against the lung disease Covid-19 and the victory of Democrat Joe Biden in the US presidential election.
Profit-taking from Nasdaq heavyweights such as Amazon, Facebook and Microsoft, on the other hand, weighed on the indices on the tech exchange. The NASDAQ 100 continued the losses from Monday and was 1.68 percent in the red at 11,632 points. The market-wide S&P 500 fell 0.37 percent to 3537 points. This index had also reached a record high the day before.
Amazon fell 3.3 percent. The world’s largest online retailer (Amazon) violates antitrust regulations according to the assessment of EU competitors. The EU Commission accuses the company of systematically using non-public business data from independent retailers for its own retail business. If the competitors stay with their assessment, Amazon threatens a billions in penalty payment.
The shares of the pharmaceutical wholesaler Walgreens Boots Alliance sat at the top of the Dow, they rose by 8 percent. The investment bank Morgan Stanley identified additional sales potential of 8.5 billion US dollars for the company should it play an important role in the distribution of a corona vaccine in the United States.
Biontech papers (BioNTech) rose by another 5 percent after climbing 14 percent the day before. Pfizer, however, fell 1 percent. The day before, positive study results on a corona vaccine had pushed the papers of the two cooperation partners and also the stock markets up sharply.
CureVac’s US-traded papers advanced 6 percent. They benefited from interim results of a study on a Covid-19 vaccine candidate from the biopharmaceutical company. Like Biontech, Curevac from Tbingen is also working at full speed on a vaccine against the coronavirus.
The meat substitute manufacturer Beyond Meat suffered heavily from the Corona crisis in the third quarter and clearly fell short of expectations. The bottom line was a loss of $ 19.3 million. The revenue of the company, which is actually known for its rapid growth, only increased by a meager 2.7 percent. The shares fell by 17 percent./bek/he
–
